Phase II Study of Weekly Genexol-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Samyang Biopharmaceuticals Corporation
- 16 Apr 2018 Planned End Date changed from 1 Feb 2018 to 1 Dec 2019.
- 16 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2019.
- 27 Apr 2017 Status changed from not yet recruiting to recruiting.